Exosome Formulation Development & Stability Solutions
OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs
Overview
At Creative BioMart Microbe, we provide end-to-end formulation development and stability solutions purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), probiotic-derived exosomes, fungal EVs, and phage-derived vesicles. Our platform integrates stability baseline profiling, buffer and excipient optimization, lyophilized and liquid formulation development, accelerated and long-term stability testing, and critical quality attribute (CQA) mapping into a single, milestone-driven workflow. Unlike mammalian exosome CDMOs that apply generic pharmaceutical formulations to microbial vesicles, we have optimized every buffer system, cryoprotectant screen, and release-criteria assay for the unique lipidome, surface charge, and immunogenic profile of microbial membranes.
Formulation stability acts as the critical bridge between upstream production and downstream therapeutic application. Our clients frequently integrate this service with upstream strain engineering and fermentation optimization to ensure that production parameters align with formulation requirements, and with functional validation to confirm that stabilized vesicles retain their intended bioactivity. For a complete view of our capabilities, explore the full Microbial Exosome Services portfolio, which also includes isolation and purification solutions. Contact us to discuss how these services can be integrated into your development pipeline.
Figure 1. Schematic overview of the integrated formulation development and stability platform, spanning stability baseline assessment, formulation design, lyophilization and liquid formulation optimization, accelerated and long-term stability profiling, and CQA-linked release criteria.
Services
Service Workflow
Service Details
Exosome Stability Studies
We conduct multi-dimensional stability assessments tailored to microbial vesicles. Our protocols evaluate storage temperature gradients, freeze-thaw cycle tolerance, transport simulation, buffer compatibility, and functional shelf-life monitoring. Physical stability is tracked by particle size distribution, zeta potential, and morphological integrity via NTA, DLS, and cryo-TEM. Functional stability is monitored through cell uptake efficiency, cargo transfer rates, and bioactivity retention over time. We generate stability trend reports with statistical modeling to predict shelf-life under defined storage and distribution conditions.
Exosome Formulation Development
We develop liquid, lyophilized, and sustained-release formulations optimized for microbial exosome applications. Liquid formulations are engineered with optimized buffer systems, pH, and osmolarity to maintain colloidal stability at 2–8°C. Lyophilized formulations are developed through systematic cryoprotectant and lyoprotectant screening to maximize post-reconstitution particle recovery and functional retention. For sustained-release applications, we evaluate exosome-embedded hydrogels, microspheres, and lipid-coated systems, tracking burst-effect mitigation and release-profile consistency as CQAs.
Service Specifications & QC Standards
Formulation & Stability Capability
- Supported formulation types: liquid, lyophilized, spray-dried, hydrogel composite, and microsphere-embedded.
- Stability testing dimensions: physical, chemical, functional, process-related, and transport-simulated.
- Excipient library: sugars, amino acids, polymers, lipids, and buffers screened for microbial vesicle compatibility.
- QC standards aligned with MISEV2023 guidelines; GxP-compliant formats available for regulatory submissions.
Typical Data Range
- Post-lyophilization particle size shift: <15% vs. native vesicles.
- Zeta potential stability in optimized liquid buffer: maintained within ±5 mV over 4 weeks at 2–8°C.
- Functional shelf-life half-life: 2–6 months at 4°C for liquid formulations; 12–24 months at 25°C for lyophilized formulations.
- Freeze-thaw integrity retention: >85% after three cycles in optimized cryoprotectant.
- Batch-to-batch release-profile CV: <20%.
- Endotoxin level for in vivo-grade samples: <0.5 EU/mL.
Turnaround Time
| Project Type |
Timeline |
| Stability baseline assessment |
2–3 weeks |
| Liquid formulation optimization |
2–4 weeks |
| Lyophilized formulation development |
4–6 weeks |
| Spray-dried powder formulation |
4–6 weeks |
| Accelerated stability study (ICH conditions) |
4–8 weeks |
| Long-term stability study |
3–12 months |
| CQA documentation and regulatory package |
2–3 weeks |
| Integrated formulation-to-stability project |
8–14 weeks |
Timeline may vary based on formulation complexity, strain background, and assay customization.
Deliverables
- Experimental protocols and SOP summaries.
- Raw data files (NTA, DLS, cryo-TEM, flow cytometry, HPLC chromatograms).
- Processed analytical reports with statistical analysis and publication-ready charts.
- Stability trend reports with shelf-life modeling and mechanism interpretation.
- Certificate of Analysis (CoA) per batch.
- Lyophilization cycle development report (if applicable).
- Formulation-to-CQA mapping documentation.
- Optional GxP-aligned CQA package for IND-enabling studies.
Quality Control
- Batch-level instrument calibration with certified positive and negative controls.
- Inter-batch consistency assessment (particle size CV <15%, release-profile CV <20%).
- MISEV2023 compliance checklist for all formulation and stability assays.
- Contaminant screening for residual excipients, unencapsulated free cargo, and organic solvents.
- Endotoxin monitoring for all in vivo-grade samples.
- Optional GxP-aligned assay validation and CQA trending analysis for lot-release documentation.
Sample Requirements
| Required Information |
Optional Information |
Not Accepted |
- Sample type (purified microbial exosomes, fermentation supernatants, lyophilized exosomes, conditioned media, live engineered strains)
- Estimated particle concentration or total protein yield
- Strain background and culture conditions
- Target formulation type (liquid, lyophilized, spray-dried, composite)
- Sample volume (≥500 μL recommended for in vitro; ≥1 mL for multi-parameter stability; ≥10 mL for formulation development)
- Endotoxin level (for in vivo studies)
- Desired stability endpoints or shelf-life targets
|
- Prior isolation method (TFF, SEC, ultrafiltration, density gradient, or other)
- Target application (research, CMC, regulatory filing, publication, food-grade, cosmetic-grade, GMP)
- Specific stability challenges (GI exposure, serum exposure, room-temperature distribution)
- Special formulation requests (enteric coating, sustained-release matrix, topical base compatibility)
- Control sample requirements (untreated, vehicle-only, empty vesicle, or competitor benchmark)
- Regulatory documentation requirements (CoA, SOP, CQA package)
|
- Samples subjected to more than three freeze-thaw cycles
- Samples with unidentified strain origin or undocumented culture conditions
- Severely degraded, contaminated, or detergent-heavy preparations
- Samples preserved with fixatives, antimicrobial agents, or non-sterile buffers
- Samples shipped at inadequate temperature or with compromised cold-chain documentation
|
Recommended Sample Quantity by Application:
| Application |
Recommended Amount |
| Stability baseline assessment |
≥200 μg total protein or 2×109 particles |
| Liquid formulation optimization |
≥500 μg total protein |
| Lyophilized formulation development |
≥1 mg total protein |
| Spray-dried powder development |
≥1 mg total protein |
| Accelerated stability study |
≥1 mg total protein |
| Long-term stability study |
≥2 mg total protein |
| Multi-batch consistency validation |
≥3 batches, ≥1 mg per batch |
| In vitro functional validation |
≥300 μg total protein |
| In vivo pilot studies |
≥1 mg total protein |
Storage & Shipping: Ship frozen at –80°C on dry ice. Store at –80°C upon receipt. Avoid repeated thawing. Recommended buffer: sterile PBS, pH 7.4, endotoxin-free. Live engineered strains should be shipped on glycerol stocks or agar stabs with cold-chain documentation.
Our Advantages
- Microbial EV Formulation Specialization: Deep expertise in bacterial OMVs, probiotic EVs, and fungal vesicles. Every buffer system, cryoprotectant screen, and release-criteria assay is optimized for microbial membrane composition, not adapted from mammalian templates.
- Dual-Track Stability Assessment: Physical stability (particle size, zeta potential, morphology) and functional stability (cell uptake, cargo delivery efficiency, bioactivity retention) are evaluated in parallel, defining functional shelf-life rather than physical shelf-life alone.
- Formulation-to-CQA Mapping: Each formulation parameter is directly mapped to critical quality attributes and intended clinical outcomes, with stage-appropriate CMC documentation from exploratory phase through IND submission.
- Cold-Chain Alternative Expertise: Lyophilization, spray-drying, and room-temperature-stable liquid formulations reduce distribution dependency on cold-chain logistics, enabling global supply reach.
- Closed-Loop Formulation-Stability Validation: Formulation development does not conclude at recipe finalization. Every formulation is linked to accelerated and long-term stability data, batch-to-batch consistency matrices, and regulatory release-ready data packages in a single integrated deliverable.
Applications
Injectable Formulations for Therapeutic Delivery
Liquid and lyophilized formulations for intravenous, intramuscular, or intratumoral administration, optimized for tumor immunotherapy and systemic mEV delivery with serum stability.
Oral & GI-Resistant Formulations
Enteric-coated microspheres, pH-responsive hydrogels, and probiotic composites engineered for gastric survival, intestinal release, and gut-barrier repair.
Topical & Transdermal Delivery Systems
Exosome-embedded gels, emulsions, and nanoemulsions for dermatological and cosmetic use, optimized for skin penetration and anti-inflammatory potency.
Inhalation & Dry-Powder Formulations
Nebulizer solutions and spray-dried powders for dry-powder inhaler (DPI) devices, engineered for respiratory targeting in asthma, COPD, and acute respiratory distress syndrome (ARDS) with validated aerosolization stability.
Case Study
Case Study 1: Standardized Bacterial Extracellular Vesicle Purification Protocol
Researchers proposed a unified workflow for bacterial extracellular vesicle isolation to address reproducibility challenges across laboratories. The protocol integrates differential centrifugation, tangential flow filtration, size-exclusion chromatography, and density gradient centrifugation as core steps, with strain-specific optimization of growth phase, buffer composition, and centrifugal parameters. Quality control emphasizes outer membrane protein validation, nanoparticle tracking analysis, and minimal freeze-thaw handling. The framework distinguishes genuine vesicles from cell debris and death-associated particles, enabling scalable production compatible with good manufacturing practice. This standardized approach supports consistent physicochemical characterization and functional validation, critical for advancing bacterial extracellular vesicles as therapeutic platforms and diagnostic biomarkers.
Figure 2. Minimal-optimal suggested protocol for bacterial EV isolation. (Choi, et al., 2025)
FAQs
Q: What types of exosome formulations do you develop?
A: We develop liquid formulations, lyophilized powders, spray-dried powders, hydrogel composites, microsphere-embedded systems, and lipid-coated formulations. Each is optimized for microbial vesicle stability and the intended route of administration.
Q: What dimensions are covered in your stability studies?
A: Our stability studies cover physical stability (particle size, zeta potential, morphology), chemical stability (protein and lipid integrity, surface marker retention), functional stability (cell uptake, cargo delivery, bioactivity), process-related stability (pre- and post-purification integrity), and transport-simulated stability (freeze-thaw cycles, temperature excursions).
Q: What are the advantages of lyophilized exosomes over liquid formulations?
A: Lyophilized formulations eliminate cold-chain dependency, extend shelf-life to 12–24 months at room temperature, and simplify global distribution. Reconstitution protocols are optimized to recover >85% particle integrity and functional activity.
Q: How do you assess functional shelf-life, not just physical stability?
A: We monitor bioactivity retention—such as target-cell uptake efficiency, cargo transfer rates, and pathway activation—over the same storage timeline as physical parameters. This ensures that the formulation remains therapeutically effective, not merely structurally intact.
Q: Do you provide excipient screening services?
A: Yes. We screen sugars, amino acids, polymers, lipids, and buffers to identify optimal cryoprotectants, lyoprotectants, and anti-aggregation agents for your specific microbial vesicle type and application.
Q: Do your formulation services support GMP compliance and IND documentation?
A: Yes. We provide comprehensive CoA, SOP summaries, method validation records, batch-to-batch consistency data, and optional GxP-aligned CQA documentation suitable for IND submissions, cosmetic raw-material registration, and food-grade safety filings.
Q: What is the typical project timeline?
A: Baseline stability assessment takes 2–3 weeks. Liquid formulation optimization takes 2–4 weeks. Lyophilized or spray-dried formulation development takes 4–6 weeks. Accelerated stability studies under ICH conditions take 4–8 weeks. Long-term stability studies span 3–12 months depending on the regulatory requirement.
Q: What are your sample requirements?
A: We require purified microbial exosomes, fermentation supernatants, or live engineered strains with documented background and culture conditions. We recommend ≥500 μg total protein for baseline assessment and ≥1 mg for full formulation development. We do not accept samples with more than three freeze-thaw cycles, unidentified strain origins, or fixative preservatives.
References:
- Choi, D., & Lee, E. Y. (2025). Standardizing bacterial extracellular vesicle purification: a call for consensus. Journal of Microbiology and Biotechnology, 35, e2506011.
Related Services:
